SUTR Stock Sutro Biopharma, Inc.
USLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Antibody-drug conjugate pipeline catalysts provide significant valuation leverage from current depressed levels.
Future value: $52.43 (+355.90%) · 6-12 months
Signal breakdown
- ▸Barclays maintained Buy with a $56 target.
Is SUTR a buy right now?
Our screen: ACCUMULATE (score 1) — Antibody-drug conjugate pipeline catalysts provide significant valuation leverage from current depressed levels.
Computed from end-of-day data; not personal advice.
Our track record with SUTR
First flagged in our daily picks as ACCUMULATE on 2026-10-21 at $11.50 — +0% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.